Evidence map›Paper›PMID 27922026›Full record

Trial reportThe American journal of gastroenterology2017

Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial.

Christopher C Thompson, Barham K Abu Dayyeh, Robert Kushner, Shelby Sullivan, Alan B Schorr, Anastassia Amaro, Caroline M Apovian, Terrence Fullum, Amir Zarrinpar, Michael D Jensen and 23 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04306445 (The Effect of a Gas-filled Intragastric Balloon or Endoscopic Sleeve Gastroplasty for Weight Loss Compared With a Meal Replacement Weight Loss Program on Gastric Emptying, Hormonal Adaptation to Weight Loss, and Hunger), which is not on this map. Cited by 65 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 6 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04306445 naterminatednot on this mapstarted 2020, after this paper: background citation

The Effect of a Gas-filled Intragastric Balloon or Endoscopic Sleeve Gastroplasty for Weight Loss Compared With a Meal Replacement Weight Loss Program on Gastric Emptying, Hormonal Adaptation to Weight Loss, and Hunger

TypeinterventionalSponsorUniversity of Colorado, DenverRan2020 to 2024Enrolled3ConditionsObesityArmsGF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 6 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Endoscopic bariatrics: Current status and emerging technologies.World journal of gastrointestinal endoscopy · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Endobariatric systems: Strategic integration of endoscopic therapies in the management of obesity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  12. Article
  13. Review
  14. Endoscopic Bariatric Therapy for Obesity and Metabolic Syndrome.The Korean journal of helicobacter and upper gastrointestinal research · 2023
    Review
  15. Review
  16. Endoscopic removal of a weight-loss device with stoma closure using a tack-and-suture device.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2023
    Article
  17. Overview on the endoscopic treatment for obesity: A review.World journal of gastroenterology · 2023
    Review
  18. Metabolic and Bariatric Endoscopy: A Mini-Review.Life (Basel, Switzerland) · 2023
    Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 13 institutions in 1 country.

Christopher C ThompsonDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Barham K Abu DayyehDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Robert KushnerDivision of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Shelby SullivanDivision of Gastroenterology, Washington University in St Louis, St Louis, Missouri, USA.
Alan B SchorrDivision of Endocrinology, St Mary Medical Center, Langhorne, Pennsylvania, USA.
Anastassia AmaroDivision of Endocrinology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Caroline M ApovianNutrition and Weight Management Center, Boston Medical Center, Boston, Massachusetts, USA.
Terrence FullumDivision of Minimally Invasive and Bariatric Surgery, Howard University, Washington, District of Columbia, USA.
Amir ZarrinparDivision of Gastroenterology, University of California, San Diego, California, USA.
Michael D JensenDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Adam C SteinDivision of Gastroenterology and Hepatology, Northwestern University School of Medicine, Chicago, Illinois, USA.
Steven EdmundowiczWashington University in St Louis, St Louis, Missouri, USA.
Michel KahalehDivision of Gastroenterology, Weill Cornell Medical College, New York, New York, USA.
Marvin RyouDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J Matthew BohningDivision of Gastroenterology, St Mary Medical Center, Langhorne, Pennsylvania, USA.
Gregory GinsbergDivision of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Christopher HuangSection of Gastroenterology, Boston Medical Center, Boston, Massachusetts, USA.
Daniel D TranCenter for Wellness and Weight Loss Surgery, Howard University, Washington, District of Columbia, USA.
Joseph P GlaserVA San Diego Healthcare System, San Diego, California, USA.
John A MartinNorthwestern University School of Medicine, Chicago, Illinois, USA.
David L JaffeDivision of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Francis A FarrayeSection of Gastroenterology, Boston Medical Center, Boston, Massachusetts, USA.
Samuel B HoSection of Gastroenterology, VA San Diego Healthcare System, San Diego, California, USA.
Nitin KumarDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Donna HarakalNorthwestern University School of Medicine, Chicago, Illinois, USA.
Meredith YoungWashington University in St Louis, St Louis, Missouri, USA.
Catherine E ThomasWeill Cornell Medical College, New York, New York, USA.
Alpana P ShuklaWeill Cornell Medical College, New York, New York, USA.
Michele B RyanBrigham and Women's Hospital, Boston, Masachusetts, USA.
Miki HaasSt Mary Medical Center, Langhorne, Pennsylvania, USA.
Heidi GoldsmithAspire Bariatrics, Inc., King of Prussia, Pennsylvania, USA.
Jennifer McCreaAspire Bariatrics, Inc., King of Prussia, Pennsylvania, USA.
Louis J AronneWeill Cornell Medical College, New York, New York, USA.
Brigham and Women's Hospital · USCornell University · USBoston Medical Center · USNorthwestern University · USSt. Mary Medical Center · USUniversity of Pennsylvania · USHoward University · USVA San Diego Healthcare System · USWashington University in St. Louis · USWinnMed · USMayo Clinic · USUniversity of California, San Diego · USUniversity of Colorado Denver · US

Funding

Training Grant in GastroenterologyT32DK007202 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 1985 to 2022
$7.7M
NIDDK NIH HHS T32 DK007202
6 · The paper itself

Abstract

objectivesThe AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in conjunction with lifestyle (diet and exercise) counseling.

methodsIn this 52-week clinical trial, 207 participants with a body-mass index (BMI) of 35.0-55.0 kg/m

resultsAt 52 weeks, participants in the AspireAssist group, on a modified intent-to-treat basis, had lost a mean (±s.d.) of 31.5±26.7% of their excess body weight (12.1±9.6% total body weight), whereas those in the Lifestyle Counseling group had lost a mean of 9.8±15.5% of their excess body weight (3.5±6.0% total body weight) (P<0.001). A total of 58.6% of participants in the AspireAssist group and 15.3% of participants in the Lifestyle Counseling group lost at least 25% of their excess body weight (P<0.001). The most frequently reported adverse events were abdominal pain and discomfort in the perioperative period and peristomal granulation tissue and peristomal irritation in the postoperative period. Serious adverse events were reported in 3.6% of participants in the AspireAssist group.

conclusionsThe AspireAssist System was associated with greater weight loss than Lifestyle Counseling alone.

Indexed as

Diet TherapyExercise TherapyAbdominal PainAdultDrainageFemaleGastrostomyGranulation TissueHumansMaleMiddle AgedObesityPostoperative ComplicationsTreatment OutcomeWeight Loss

Identifiers

PMID27922026
PMCPMC5350543
OpenAlexW2560187051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.